2 completed. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 2 | Completed 2 |
Follow TKM-080301: new trials by email Literature Review of TKM-080301 trials Research Report on TKM-080301
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma TKM-080301 - Hepatocellular Carcinoma, Hepatoma | Phase 1 / Phase 2 | Completed | Arbutus Biopharma Corporation | 43 | 2014-06-01 | 2019-01-16 |
| A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients TKM-080301 - Cancer, Neuroendocrine Tumors | Phase 1 / Phase 2 | Completed | Arbutus Biopharma Corporation | 68 | 2010-12-01 | 2019-01-16 |
Adrenocortical Carcinoma (1) · Carcinoid Tumor (1) · Carcinoma, Hepatocellular (1) · Hodgkin Disease (1) · Liver Neoplasms (1) · Lymphoma, Non-Hodgkin (1) · Neoplasms (1) · Neuroendocrine Tumors (1)
Arbutus Biopharma Corporation (2)
United States (2) · Canada (1) · China (1) · Singapore (1) · South Korea (1) · Taiwan (1)
Mark Kowalski, M.D., Ph.D. (1) · Mark Kowalski, MD (1)